TSRI Study Identifies New Type of Protein Clump that May Be Implicated in ALS
The Findings May Lead to New Therapies for ALS and Other Neurodegenerative Conditions
“We have uncovered a new molecular mechanism underlying neurodegeneration,” said Claudio Joazeiro, associate professor of cell and molecular biology at The Scripps Research Institute (TSRI) and senior author of the new study. “This could lead to new diagnostics or new therapeutic approaches, especially for ALS.” This new mechanism, or specific enzyme, can “tag” certain types of proteins to send them to join clumps. These clumps protect against neurodegenerative disease such as ALS, or Lou Gehrig’s disease. These findings provide a new perspective on the role of protein clumps that have previously been associated with some types of neurological disease. Click here to read more.
GOODMAN Oral Board Preparation Course Tumor
Nov. 1-3, 2017; Glendale, Ariz.
2017 Managing Coding and Reimbursement Challenges
Aug. 17-19, 2017; Chicago
2017 From Cranial to Spine: An Overview of Neurosurgical Topics for the Advanced Practice Provider
Aug. 30-Sept. 2, 2017; Chicago
Mayo Clinic Neuroscience and Oncology Innovation Summit 2017
Sept. 7-9, 2017; Orlando, Fla.
63rd Annual Meeting of the Western Neurological Society
Sept. 8-11, 2017; Banff, Alberta, Canada